|
Comparative effectiveness research is an emerging field that compares the relative effectiveness of alternative strategies to prevent, diagnose, or treat patients who are typical of day-to-day practice. Dr Cheifetz and colleagues developed a priority list of comparative effectiveness research topics for inflammatory bowel disease. Following the Institute of Medicine's approach, the researchers developed and administered a survey to gastroenterologists asking for important comparative effectiveness research topics in inflammatory bowel disease. The team convened 2 patient focus groups to solicit additional comparative effectiveness research studies. The researchers presented comparative effectiveness research topics to the expert panel using the RAND/UCLA methodology. Following initial ratings, the panel met to discuss and re-rate priorities. The team reported that the top 10 comparative effectiveness research topics were identified using a point-allocation system.  | | A point-allocation system prioritized the top-10 comparative effectiveness research topics | | Inflammatory Bowel Diseases |
Responses were collated into 234 comparative effectiveness research topics across 21 categories, of which 87 were prioritized for discussion and re-rated. The doctors observed that there was a disagreement regarding priorities that was observed in 5 of 87 studies. The researchers utilized a point-allocation system to prioritize the top-10 comparative effectiveness research topics. Those related to comparing the effectiveness of: biomarkers in inflammatory bowel disease included withdrawal of anti-tumor necrosis factor or immunomodulators for Crohn's disease in remission, mucosal healing as an endpoint of treatment, and infliximab levels versus standard infliximab dosing. The team also examined anti-anti-tumor necrosis factor monotherapy versus combination therapy in patients failing thiopurines, safety of long-term treatment options, anti-anti-tumor necrosis factor versus thiopurines for prevention of postoperative recurrence, and treatment options for steroid-refractory ulcerative colitis. Dr Cheifetz commented "We systematically developed a list of high-priority inflammatory bowel disease topics for comparative effectiveness research based on a survey of gastroenterologists, expert review, and patient input." "This list may guide inflammatory bowel disease research toward the most important comparative effectiveness research studies."
| 
Email this page to a colleague
